TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06559150: A Phase II, Randomized, Double-Blind, Placebo- Controlled Study of Ensifentrine in Subjects With Non-Cystic Fibrosis Bronchiectasis

Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 284 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$8,291,500

Rescue Site Savings

+$5,459,000

Unlock Full NCT06559150 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06559150 Rescue Dossier →